Business Context and Reporting Period
This Form 8-K filing by Recursion Pharmaceuticals, Inc. (RXRX) covers the reporting period ending April 28, 2026. The report addresses corporate governance changes regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters rather than financial performance.
Material Changes
The primary material change reported is the departure of Christopher Gibson, Ph.D., from the Board of Directors. Dr. Gibson, who serves as Chair of the Board and a member of the Research and Development, Technology, and Corporate Social Responsibility Committees, will not stand for re-election as a Class II Director at the 2026 Annual Meeting of Stockholders. The filing explicitly states this decision did not result from any disagreement with the Company regarding operations, policies, or practices. Dr. Gibson will remain in his current roles until the expiration of his term at the Annual Meeting.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on business outlook, or specific risk factors beyond the standard disclosure regarding the Board transition. A press release detailing this transition was issued on April 30, 2026, and is attached as Exhibit 99.1.
Investor Verification Checklist
- Verify the date and agenda of the 2026 Annual Meeting of Stockholders to confirm the exact timing of Dr. Gibson's term expiration.
- Review the attached press release (Exhibit 99.1) for any additional context on the Board's succession planning.
- Monitor subsequent filings for the appointment of a new Chair or Class II Director to replace Dr. Gibson.
- Confirm that no other undisclosed disagreements exist between the departing director and management, as stated in the filing.